Longitudinal and Seasonal Trends in Reimbursed and Non-Reimbursed Methylphenidate Dispense and Its Most Common
Natan Van Wichelen1, Tim Boogaerts1, Arzo Raeime1
1Toxicological Centre, University of Antwerp, Antwerp, Belgium.
Purpose:
The dispense of methylphenidate (MPH) for attention-deficit hyperactivity disorder (ADHD) treatment often raises concerns about overdiagnosis, over-, mis-, and abuse. However, in-depth temporal analyses on dispensing and reimbursement data are lacking in Belgium and globally.
Methods:
Longitudinal trends in the dispensing of MPH and its alternatives, including atomoxetine (ATO), modafinil (MOD), and guanfacine (GUA), were analyzed from 2011 to 2022 in Belgium using data from IFSTAT and IQVIA databanks. The dataset uniquely separates MPH and MOD into reimbursed and non-reimbursed categories across age groups (6-17 and > 17 years). These trends were further examined in the context of international literature to provide a comprehensive framework for comparison.
Results:
MPH is the most prescribed ADHD medication. Over the 12-year study period, all included drugs showed an increasing trend. For MPH and MOD, this rise is driven by non-reimbursed dispensing, while reimbursed dispensing remained stable. During summer months, a seasonal drop in MPH dispensing for the 6-17Y age group suggests an annual 'MPH drug holiday' to evaluate the necessity of continued use. While comprehensive pharmacovigilance is currently limited by insufficient demographic data and specific prescription indications, addressing these gaps presents an opportunity to better understand the underlying causes of observed dispensing trends.
Conclusion:
Differentiating between reimbursed and non-reimbursed dispensing is crucial to accurately describe the increasing use of this group of ADHD medication. More granular data is needed to assess whether changes to prescribing practices are necessary and to inform future development of guidelines.
Insights
Dispensing of methylphenidate (MPH) for attention-deficit hyperactivity disorder (ADHD) increased, driven by non-reimbursed prescriptions. A seasonal drop in MPH use among children suggests annual "drug holidays" to assess treatment necessity.
Area of Science:
- Pharmacology and Public Health
- Medication Dispensing Trends
- Attention-Deficit Hyperactivity Disorder (ADHD) Treatment
Background:
- Methylphenidate (MPH) is a primary medication for ADHD, but concerns exist regarding overdiagnosis and misuse.
- Limited temporal analyses exist on MPH dispensing patterns and reimbursement data globally and in Belgium.
- Understanding dispensing trends is crucial for effective ADHD management and pharmacovigilance.
Purpose of the Study:
- To analyze longitudinal trends in MPH and alternative ADHD medication dispensing in Belgium from 2011 to 2022.
- To investigate the impact of reimbursement status on dispensing patterns for MPH and modafinil (MOD).
- To compare Belgian dispensing trends with international literature for a broader context.
Main Methods:
- Utilized IFSTAT and IQVIA databanks for longitudinal dispensing data (2011-2022).
- Separated MPH and MOD dispensing into reimbursed and non-reimbursed categories across age groups (6-17 and >17 years).
- Examined trends in MPH, atomoxetine (ATO), modafinil (MOD), and guanfacine (GUA) dispensing.
Main Results:
- All analyzed ADHD medications showed an increasing dispensing trend over the 12-year period.
- The rise in MPH and MOD dispensing was primarily attributed to non-reimbursed prescriptions, while reimbursed dispensing remained stable.
- A seasonal decrease in MPH dispensing for children (6-17 years) suggests potential annual 'drug holidays' to re-evaluate treatment necessity.
Conclusions:
- Distinguishing between reimbursed and non-reimbursed dispensing is essential for accurate interpretation of ADHD medication use.
- Increased granularity in dispensing data, including demographic information and prescription indications, is needed.
- Further data is required to inform potential adjustments to prescribing practices and ADHD treatment guidelines.
More Related Videos
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
01:15Drug Abuse and Addiction: Pharmacological Phenomena
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...